Dermatophytic Onychomycosis Treatment Market By Treatment Type (Oral/Systemic Antifungal Medications [Terbinafine, Itraconazole, Fluconazole, Fosravuconazole, Other Systemic Antifungals], Topical Antifungal Drugs [Efinaconazole, Tavaborole, Ciclopirox, Luliconazole, Topical Terbinafine, Other Topical Antifungals], Procedural Treatments [Mechanical Debridement, Chemical Debridement, Laser Therapy, Photodynamic Therapy, Partial & Total Nail Avulsion]), By End User (Dermatology Clinics, Podiatry Clinics, Hospitals & Specialty Clinics, Homecare & Other Treatment Settings), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Dermatophytic Onychomycosis Treatment Market: From Nail Infection to Global Pharma Battleground

The Global Dermatophytic Onychomycosis Treatment Market was valued at USD 5.96 billion in 2025 and is projected to reach USD 9.57 billion by 2032, expanding at a CAGR of 7.0% during 2026–2032.

 

The Global Dermatophytic Onychomycosis Treatment Market, which refers to the pharmaceutical and procedural therapies used to manage fungal infections of the nail caused specifically by dermatophyte organisms, is supported by a large persistent patient pool, increasing treatment among older and medically complex patients, broader use of prescription topical antifungals, recurring podiatry procedures, and new topical drug-delivery approaches designed to narrow the efficacy gap between oral and local treatment. The commercial market remains unusual because low-cost generic oral terbinafine provides the principal efficacy benchmark, while branded pharmaceutical revenue is concentrated in topical therapies used by patients who cannot, should not, or prefer not to receive systemic treatment.

 

FDA-approved pharmacologic options for dermatophytic onychomycosis include systemic and topical agents with distinct mechanisms of action. Oral terbinafine (Lamisil) is the first-line systemic therapy and acts as a squalene epoxidase inhibitor, causing ergosterol depletion and toxic squalene accumulation in dermatophytes. Itraconazole (Sporanox) and fluconazole (Diflucan, off-label use) are triazole antifungals that inhibit lanosterol 14-α-demethylase (CYP51), thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.

 

Topical FDA-approved therapies include efinaconazole 10% solution (Jublia), a triazole (CYP51 inhibitor) with strong nail plate penetration; tavaborole 5% solution (Kerydin), a boron-based antifungal that inhibits leucyl-tRNA synthetase, thereby blocking fungal protein synthesis; and ciclopirox 8% lacquer (Penlac), a hydroxypyridone antifungal that chelates metal ions and disrupts fungal enzyme systems and cellular metabolism.

 

Globally, it is estimated that around 5–10% of the general population has some form of nail fungal infection, which translates to over 400–500 million people worldwide when including all types of onychomycosis. In the United States alone, studies suggest that approximately 35–40 million people are affected, with higher rates in older adults where prevalence can exceed 20–25% in those above 60 years of age. The condition is more common in people with diabetes, poor circulation, or weakened immunity, making these groups a key focus for treatment. Overall, the disease represents a large, chronic, and under-treated patient pool, with most cases remaining untreated or self-managed despite available prescription therapies.

 

Why Does Oral Terbinafine Continue to Set the Commercial Benchmark?

Oral terbinafine remains the core systemic treatment against which new dermatophytic onychomycosis therapies are compared. U.S. prescribing information specifies 250 mg once daily for six weeks for fingernail disease and 12 weeks for toenail disease. Baseline evaluation for liver disease and liver-function testing are recommended because clinically significant hepatotoxicity can occur.

Its position is reinforced by efficacy rather than simply prescribing habit. A cumulative meta-analysis of systemic antifungals reported an average mycological cure rate of about 76% for terbinafine, compared with 63% for pulse itraconazole, 59% for continuous itraconazole, and 48% for fluconazole. A separate systematic review concluded that continuous terbinafine 250 mg daily for three months was the most effective oral treatment among the evaluated regimens for fungally infected toenails.

U.S. real-world prescribing follows the same hierarchy. Among 18,128 commercially insured patients who received an oral antifungal in a U.S. claims analysis, 88.2% received terbinafine. Only 9.7% of patients prescribed oral antifungal therapy had confirmatory diagnostic testing recorded.

The commercial implication is important. New systemic therapies are not entering an untreated pharmacological space; they must compete against an inexpensive generic with a relatively short course and strong physician familiarity. Higher-value opportunities are consequently concentrated among patients who cannot receive terbinafine because of liver disease, drug interactions, previous treatment failure, resistant organisms, intolerance, or a preference to avoid systemic exposure.

Itraconazole continues to provide an alternative systemic option, particularly where terbinafine is inappropriate or the causative organism creates a different susceptibility profile. Fluconazole provides another physician-selected alternative and is used off-label for onychomycosis in the United States. However, neither has displaced terbinafine as the principal systemic benchmark.

 

Why Are Topical Antifungals Still Capturing Premium Treatment Revenue?

Topical antifungals occupy the most commercially differentiated part of the pharmaceutical market. Their primary advantage is avoiding systemic exposure; their principal limitation is the need to deliver sufficient active drug through dense nail keratin and sustain treatment over many months.

Efinaconazole 10% has established one of the strongest positions among prescription topicals. U.S. pivotal studies of Jublia reported complete cure rates of approximately 17.8% and 15.2%, with treatment administered for 48 weeks and efficacy assessed after treatment completion. The product is specifically indicated for toenail onychomycosis caused by Trichophyton rubrum and T. mentagrophytes.

The commercial appeal of efinaconazole is therefore not that it outperforms oral terbinafine. Its value is concentrated among patients and prescribers prioritizing non-systemic treatment while seeking greater topical efficacy than older lacquers can typically deliver.

Tavaborole 5% occupies a similar non-systemic position but faces greater efficacy and generic-pricing pressure. Its pivotal trials reported complete cure rates of 6.5% and 9.1% after a 48-week once-daily regimen. Generic competition has already changed this segment. FDA records show that the first generic tavaborole was approved in October 2020, while FDA Paragraph IV records list 13 submitted ANDAs against the Kerydin reference product.

Ciclopirox 8% lacquer remains commercially relevant because its generic status makes it substantially easier for payers to position ahead of premium topical products. Its lower complete-cure performance is offset by affordability and widespread familiarity. That makes ciclopirox not merely an older treatment but an important payer-controlled gatekeeper for branded topical adoption.

This distinction can be seen directly in Medicaid policy. Oklahoma's current criteria require patients seeking Jublia or Kerydin to have undergone a 12-week trial of oral antifungal treatment and to have a clinically significant reason they cannot use ciclopirox. Cosmetic treatment is excluded. Wisconsin ForwardHealth's July 2026 criteria for tavaborole are even more restrictive, requiring an unsatisfactory response after 48 weeks of ciclopirox, together with failure, intolerance, or a clinically relevant reason preventing oral terbinafine use.

Long treatment duration therefore affects the market twice: it can weaken patient persistence and it raises payer questions about value relative to inexpensive oral therapy. Future topical products that materially shorten treatment, improve complete cure, reduce application burden, or demonstrate stronger outcomes in oral-ineligible populations would have a clearer pathway to premium positioning.

 

How Large Is the Diagnosis and Treatment Conversion Opportunity?

A substantial part of future market growth can come from increasing the proportion of existing patients who receive appropriate confirmation and treatment rather than from rising disease prevalence alone.

The American Academy of Dermatology's DataDerm cohort included 152,850 U.S. dermatology patients diagnosed with onychomycosis from 2016 through 2022. Among patients receiving topical or oral antifungal therapy, 76.9% did not have confirmatory testing recorded before treatment. The study also identified a disproportionately high burden in the U.S. South Census region.

The earlier U.S. commercial claims analysis reached a similar conclusion. Of patients receiving an oral antifungal, fewer than one in ten had confirmatory testing recorded, despite terbinafine accounting for nearly nine in ten oral prescriptions.

For pharmaceutical companies, diagnostic laboratories, dermatologists, and podiatrists, this creates a commercially meaningful treatment-conversion issue. Laboratory confirmation becomes increasingly valuable when patients have failed standard therapy, when non-dermatophyte organisms are possible, or when resistance is suspected.

It also changes how manufacturers should approach prescribers. Dermatologists represent an important pharmaceutical channel, but podiatry adds drug prescribing, nail debridement, avulsion, and longitudinal nail-care services. Successful commercialization therefore requires access to both medical dermatology and foot-care networks rather than focusing exclusively on one specialty.

 

Where Do Debridement, Laser Therapy, and Other Procedures Fit in the Market?

Procedures represent an adjunctive treatment market rather than a substitute for antifungal drugs.

Nail debridement is particularly important because it creates recurring office-based activity and can be combined with systemic or topical therapy. The U.S. commercial insurance analysis found debridement recorded in approximately 20.5% of newly diagnosed patients.

Clinical evidence also supports the adjunctive model. In the randomized IRON-CLAD study, oral terbinafine plus aggressive debridement produced a 37.8% complete cure rate at week 48 versus 32.5% with terbinafine alone. Mycological cure was 67.5% versus 62.6%. The incremental difference is not large enough to turn debridement into a standalone replacement for pharmacotherapy, but it supports its role in severe, thickened, or difficult-to-penetrate nails.

Chemical debridement with keratolytic agents such as high-concentration urea serves a related purpose where mechanical thinning is difficult. Nail avulsion is more concentrated in severe, painful, localized, or refractory disease. Both create procedure revenue but normally remain connected to subsequent antifungal management because physical nail removal alone does not eliminate every fungal reservoir.

Laser therapy has a different commercial proposition. Patients may select device-based treatment because they want to avoid systemic medications, but published evidence remains heterogeneous across laser types, treatment schedules, endpoints, disease severity, and follow-up periods. A recent review continues to describe variable clinical results rather than evidence that laser treatment consistently displaces established antifungal pharmacotherapy.

This keeps device-based procedures concentrated in adjunctive and patient-pay settings, while drug therapy remains the principal route to mycological eradication.

 

Is Antifungal Resistance Creating a New Market Layer?

Terbinafine resistance is becoming strategically important because the dominance of a single oral first-line agent makes any sustained reduction in susceptibility commercially relevant.

U.S. surveillance has documented terbinafine-resistant T. rubrum, while T. indotineae has emerged as another difficult-to-treat dermatophyte. A U.S. survey of podiatrists found that management of difficult or laboratory-confirmed terbinafine-resistant infections included surgical nail avulsion, topical therapy, and systemic azoles, illustrating how resistance can move patients into higher-complexity treatment pathways.

The opportunity should not be overstated. Resistant isolates identified in specialized laboratories do not establish that resistance is widespread among all dermatophytic onychomycosis patients. Instead, resistance expands the value of fungal identification, susceptibility testing, alternative systemic agents, combination therapy, and topical products that can reach high drug concentrations locally.

The commercial effect is therefore likely to appear first among recurrent and treatment-failure patients rather than through immediate replacement of oral terbinafine across the broader market.

 

How Does Dermatophytic Onychomycosis Treatment Demand Differ by Region?

North America

North America represents one of the most developed prescription treatment markets, accounting for ~40% share of the global dermatophytic onychomycosis treatment market, valued at approximately USD 2.38 billion in 2025, and is projected to grow at a CAGR of 7.0% during 2026–2032, as it combines substantial dermatologist and podiatrist participation, established oral prescribing, premium prescription topicals, diagnostic laboratories, and procedure-based treatment.

The U.S. market is still dominated by generic oral terbinafine, which accounts for 88.2% of oral antifungal prescriptions in commercial insurance data. Alongside this, Bausch Health’s Jublia remains the leading branded topical therapy, while generic ciclopirox and tavaborole keep pricing pressure high in the topical segment.

A key barrier for newer treatments is payer step therapy, with Medicaid programs often requiring patients to try oral terbinafine and older generics before accessing branded topicals. This means new products must show clear advantages such as higher cure rates, better adherence, or suitability for patients who cannot use oral therapy.

North America also generates steady procedure-based revenue, with nail debridement commonly used in clinical practice. In addition, rising concern around terbinafine resistance is increasing demand for diagnostic testing and alternative treatment options in difficult cases.

 

Europe

Europe is entering a more dynamic phase as newer topical therapies move into markets historically served by systemic generic antifungals and established topical lacquers; within the global dermatophytic onychomycosis treatment market valued at USD 5.96 billion in 2025 and projected to reach USD 9.57 billion by 2032 at a CAGR of 7.0%, Europe represents a significant regional demand center, although its exact market share percentage is not separately disclosed in the available data.

A key development in Europe is the expansion of efinaconazole, licensed by Kaken Pharmaceutical to Almirall in 2021. Almirall completed EU regulatory procedures in 2024, with German approval granted in 2025, enabling rollout across European dermatology markets using its established specialist network.

Another major shift is topical terbinafine (MOB-015/Terclara) from Moberg Pharma, which has received approval in 14 countries and is already commercial in Sweden and Norway. Early performance is strong, with 38% value share in Sweden and 29% in Norway (Q1 2026 pharmacy data).

Karo Healthcare is supporting broader European expansion across 19 markets, with planned launches in 2026 using established antifungal brands like Lamisil or Pevaryl where allowed.

Overall, Europe is becoming a key competitive region where low-cost oral treatments still dominate, but newer prescription topicals like efinaconazole and MOB-015 are steadily increasing their presence.

 

Asia-Pacific

Asia-Pacific has one of the most differentiated treatment structures, particularly because Japan has adopted therapies that are not equally available across Western markets, accounting for an estimated ~35% share of the global dermatophytic onychomycosis treatment market, valued at approximately USD 2.1 billion in 2025, and is projected to expand at a CAGR of around 7.5% during the forecast period.

Japan’s nationwide claims data (2014–2021) shows that onychomycosis treatment spending rose sharply from about JPY 10.8 billion in FY2014 to JPY 36.3 billion in FY2019, largely driven by the launch of efinaconazole, while use of older oral therapies like terbinafine declined as newer options entered the market.

Japan also has strong local players. Kaken markets efinaconazole (Clenafin), while Sato Pharmaceutical offers both topical LUCONAC and oral NAILIN, making it one of the few companies with dual treatment options in this category.

In Asia-Pacific, companies are actively expanding. Sato launched LUCONAC in Singapore in 2024, while Moberg Pharma and Karo Healthcare expanded MOB-015 distribution in 2026 across Australia, New Zealand, South Korea, Taiwan, and via e-commerce into China.

Overall, Asia-Pacific is becoming a key growth region, driven by new topical antifungals, strong local brands, and expanding cross-border commercialization.

 

Latin America

Latin America remains more fragmented than North America, Western Europe, or Japan in terms of publicly documented prescription utilization and standardized treatment datasets, representing approximately 8.5% market share (~USD 0.51 billion in 2025) of the global dermatophytic onychomycosis treatment market and projected to expand at a CAGR of ~6.2% during 2026–2032. This makes reliable regional comparisons of dermatophytic onychomycosis treatment volumes difficult.

Commercially, generic systemic antifungals are likely to remain difficult for premium treatments to displace where affordability is a major purchasing consideration. Newer topical products have a clearer opportunity in private dermatology, self-pay populations, patients with systemic-treatment limitations, and markets where established consumer-health antifungal franchises provide efficient pharmacy distribution.

The current geographic strategies of the most active innovators also show that Europe and Asia-Pacific are receiving earlier expansion priority than Latin America. This suggests that near-term Latin American premium-product growth will depend more on licensing partnerships, local registration, affordability, and pharmacy access than on immediate broad launches. This is an inference from currently disclosed commercialization footprints rather than a published regional market-share statistic.

 

Middle East & Africa

The Middle East and Africa should not be treated as a single homogeneous dermatophyte market. Recent global etiological analysis found meaningful geographic differences in the proportion of dermatophytes, yeasts, and non-dermatophyte molds. That variation increases the importance of laboratory confirmation before assuming that every abnormal fungal nail is a terbinafine-sensitive dermatophyte infection, accounting for approximately 6% share of the global dermatophytic onychomycosis treatment market, valued at around USD 0.36 billion in 2025, and is projected to grow at a CAGR of 6.2% during 2026–2032.

The commercial market remains weighted toward accessible generic antifungals, while newer prescription topicals are likely to be concentrated initially in higher-income private healthcare and dermatology channels. Expansion opportunities are therefore tied to greater diagnosis, specialist access, private insurance coverage, pharmacy availability, and regional distribution partnerships.

For manufacturers, the region creates a different strategy from the United States or Japan: distribution reach and treatment affordability can matter as much as marginal differences in drug efficacy.

 

Which Companies Are Shaping the Competitive Landscape?

Bausch Health Companies Inc.

Bausch Health's principal dermatophytic onychomycosis asset is Jublia (efinaconazole topical solution 10%), marketed through its dermatology business. The product is indicated in the United States for toenail onychomycosis caused by T. rubrum and T. mentagrophytes.

Jublia gives Bausch one of the most established premium topical positions in North America. Its pivotal complete-cure rates of 15.2%–17.8% are substantially below the mycological performance expected from oral terbinafine, but its competitive value comes from avoiding systemic drug exposure and offering a prescription option for patients who are not appropriate candidates for oral treatment.

Bausch's advantage is its established U.S. dermatology infrastructure, physician familiarity, podiatry exposure, and history of supporting Jublia as a branded prescription product. Its greatest competitive challenges are generic oral terbinafine, inexpensive ciclopirox, payer step therapy, and future topical products seeking stronger efficacy.

 

Kaken Pharmaceutical Co., Ltd.

Kaken's core onychomycosis asset is efinaconazole, marketed domestically as Clenafin and internationally through partners under brands including Jublia. Clenafin remains one of Kaken's principal prescription pharmaceutical products.

Kaken is particularly important competitively because it is the originator behind an asset commercialized by different companies across multiple regions. Rather than building its own sales infrastructure everywhere, Kaken has used regional partnerships to extend efinaconazole into the United States, Canada, Europe, and Asian markets. The company specifically identifies overseas expansion of Clenafin through partners in Europe, the United States, and other countries as part of its business-development strategy.

Expansion is continuing. As of May 13, 2026, Kaken listed efinaconazole for onychomycosis in Phase III development in China through AIM. Kaken therefore combines existing product royalty/licensing exposure with further geographic expansion potential.

 

Almirall S.A.

Almirall's direct onychomycosis portfolio centers on efinaconazole/Jublia, for which it holds exclusive European development and commercialization rights from Kaken. The product complements a much broader medical-dermatology portfolio and specialist sales infrastructure.

Almirall completed the decentralized European regulatory procedure for efinaconazole in October 2024. Germany subsequently approved efinaconazole during 2025, creating an important launch platform in Europe's largest pharmaceutical market.

Its competitive advantage differs from that of a single-product antifungal company. Almirall already maintains relationships with European dermatologists through a broader medical-dermatology portfolio, allowing efinaconazole to be added to an established specialist-commercialization platform. The main challenge will be differentiating a long-duration prescription topical against inexpensive systemic therapy, established nail lacquers, and the emerging topical-terbinafine category.

 

Moberg Pharma AB

Moberg Pharma's principal pharmaceutical asset is MOB-015/Terclara, a topical terbinafine formulation developed specifically for onychomycosis. The company also has historical experience in the nail-treatment category through the earlier Kerasal Nail/Nalox franchise.

MOB-015 represents one of the most important current challenges to the conventional division between effective systemic terbinafine and lower-efficacy topical therapy. Moberg reports 76% mycological cure in its pivotal daily-dosing studies, and the product has received approval in 14 countries.

Commercial uptake in the Nordic countries provides early evidence of demand. During Q1 2026, Terclara held 38% value share in Swedish pharmacy sell-out and 29% value share in Norwegian pharmacy purchasing data, according to company-reported market information.

The development program also illustrates the risk of reducing treatment intensity. A North American Phase III trial using eight weeks of daily dosing followed by weekly maintenance did not meet its primary complete-cure endpoint, leading Moberg to concentrate on the daily regimen supporting European approvals.

Moberg's near-term strategy is therefore European and international commercialization rather than immediate U.S. disruption. Its competitive value will depend on whether Nordic adoption can be repeated in larger European markets.

 

Karo Healthcare

Karo brings an established antifungal consumer-health portfolio led by Lamisil, together with Pevaryl in selected markets. Through its partnership with Moberg Pharma, Karo is adding MOB-015/Terclara to this existing antifungal platform.

Karo's role is strategically important because it provides Moberg with an existing retail-pharmacy distribution network rather than requiring the developer to construct country-by-country commercial operations. The November 2025 collaboration covered 19 European markets with a combined population of approximately 500 million. The partnership expanded in April 2026 to Australia, New Zealand, South Korea, and Taiwan.

In June 2026, the companies expanded again into China through cross-border e-commerce, with plans to use the Lamisil brand. European launches are also being prepared using Lamisil or Pevaryl branding where national regulatory requirements permit.

Karo's advantage is therefore not novel antifungal discovery. It is brand leverage, pharmacy access, consumer-health marketing, and geographic execution. This could shorten MOB-015's commercialization curve considerably compared with building independent distribution.

 

Sato Pharmaceutical Co., Ltd.

Sato has one of the broadest company-specific prescription onychomycosis portfolios in Japan, comprising LUCONAC Solution 5%, a topical luliconazole formulation, and NAILIN Capsules 100 mg, an oral antifungal containing fosravuconazole. Sato launched LUCONAC in Japan in 2016 and NAILIN in 2018.

The combination gives Sato exposure to both local and systemic treatment decisions, rather than relying on a single therapeutic route. This is commercially significant in Japan, where nationwide claims data show that newer prescription drugs have materially reshaped onychomycosis expenditure and prescribing patterns.

Sato is also moving beyond Japan. LUCONAC was launched in Singapore in July 2024, and the company states that it is using Singapore as a base for broader Asian expansion while also pursuing antifungal development in North America.

Sato's competitive strength lies in specialist dermatology relationships, ownership of both oral and topical treatment options, and a growing Asian commercialization footprint.

 

Zydus Lifesciences Ltd.

Zydus participates primarily through generic tavaborole topical solution 5%, giving it exposure to the U.S. prescription topical market without carrying the development economics of an original branded therapy. Zydus received final FDA approval for the product in 2023.

Zydus represents an important broader competitive force: genericization of premium topical classes. FDA records show numerous ANDA filings around tavaborole, meaning manufacturers of novel topicals must compete not only with oral terbinafine and generic ciclopirox but increasingly with generic versions of newer topical agents.

This can compress pricing in the older topical segment while raising the efficacy and convenience threshold required for future branded launches.

 

Perrigo Company plc

Perrigo participates through tavaborole topical solution 5%, the first generic version of Kerydin approved by the FDA in October 2020 for toenail onychomycosis caused by T. rubrum or T. mentagrophytes.

Perrigo's role is commercially important because it marked the transition of tavaborole from a protected branded therapy into a multi-source topical category. As more generic suppliers enter, payer willingness to reimburse premium alternatives without prior treatment failure can decrease.

 

Analyst Outlook: What Will Shape the Next Competitive Phase in Onychomycosis Treatment Market?

Growth in the dermatophytic onychomycosis market will mainly come from better diagnosis, improved topical drugs, and wider global rollout rather than rising disease rates.

Oral terbinafine will stay the standard first-line therapy because it is cheap, short-course, and highly effective, making it hard for new systemic drugs to compete.

Topical treatments are the main area of innovation. Efinaconazole (Jublia) proved that patients will use long-course prescription topicals despite modest cure rates (~15–18% complete cure in trials). Newer entrants like Moberg Pharma’s MOB-015/Terclara are trying to improve outcomes by combining terbinafine’s antifungal strength with topical delivery, with early strong uptake in Nordic markets.

Diagnosis remains a major gap—U.S. data shows about 76.9% of patients are treated without confirmatory testing, highlighting missed opportunities for better-targeted therapy, especially as resistant infections become more recognized.

Competition is also increasingly regional. Bausch leads in North America with Jublia, Almirall is expanding it in Europe, Kaken continues global licensing of efinaconazole, while Moberg and Karo are scaling MOB-015 across Europe and Asia-Pacific, and Sato is expanding its dual oral-topical portfolio from Japan.

Overall, the market is shifting into four layers: low-cost oral drugs, premium prescription topicals, procedural care for difficult cases, and diagnostics. Winners will be those that combine better cure rates, easier treatment regimens, and strong regional access.

 

Dermatophytic Onychomycosis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 5.96 Billion
Revenue Forecast in 2032	USD 9.57 Billion
Overall Growth Rate	CAGR of 7.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By End User, By Geography
By Treatment Type	Oral/Systemic Antifungal Medications [Terbinafine, Itraconazole, Fluconazole, Fosravuconazole, Other Systemic Antifungals], Topical Antifungal Drugs [Efinaconazole, Tavaborole, Ciclopirox, Luliconazole, Topical Terbinafine, Other Topical Antifungals], Procedural Treatments [Mechanical Debridement, Chemical Debridement, Laser Therapy, Photodynamic Therapy, Partial & Total Nail Avulsion]
By End User	Dermatology Clinics, Podiatry Clinics, Hospitals & Specialty Clinics, Homecare & Other Treatment Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of dermatophytic nail infections, increasing treatment adoption among aging and diabetic populations, demand for non-systemic topical antifungal therapies, growing use of diagnostic confirmation, rising concern regarding antifungal resistance, expansion of prescription antifungal availability across emerging markets
Customization Option	Available upon request